Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Trial Profile

Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neo-adjuvant treatment in patients with operable Triple Negative or luminal B/HER2 normal Breast Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms GENEVIEVE
  • Most Recent Events

    • 13 Sep 2022 Long term survival results assessing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer presented at the 47th European Society for Medical Oncology Congress.
    • 30 Jul 2017 The protocol has amended for epirubicin and cyclophosphamide treatment sequence to taxane during recruitment because of low recruitment and in case of TNBC monotherapy prior to surgery was not accepted, according to results published in the European Journal of Cancer
    • 30 Jul 2017 Results published in the European Journal of Cancer
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top